Woman Man
- | Country :
- Greece
- France
- Turkey
- The 2 others...
- | organs : -
- | Specialty : -
Extract
The purpose of this randomized, Phase 2 open-label study was to assess the response rate of participants with Human Epidermal Growth Factor Receptor 2 (Her2+) locally advanced and/or metastatic breast cancer (not previously treated with chemotherapy or trastuzumab) to treatment with ixabepilone plus trastuzumab and/or docetaxel plus trastuzumab.
Inclusion criteria
- Metastatic breast cancer